|
|
 |
The 2007 HHS Public Health Emergency Medical Countermeasures Enterprise Workshop will provide an opportunity to discuss and receive individual stakeholder feedback on HHS implementation of the HHS Pandemic Influenza Plan, and the HHS PHEMCE Implementation Plan for Chemical, Biological, Radiological, and Nuclear Threats, the Project BioShield Act of 2004, and the new HHS Biomedical Advanced Research and Development Authority (BARDA) in the Pandemic and All-Hazards Preparedness Act.
WHERE:
Fairmont Washington DC, 2401 M Street, NW, Washington, DC 20037
WHEN:
July 31- August 2, 2007
HHS PANDEMIC INFLUENZA PLAN:
The National Strategy for Pandemic Influenza (November 2005) designates HHS as the lead agency for public health and medical response for pandemic preparedness and response. Effective implementation of the HHS Pandemic Influenza Plan relies on support from partners throughout HHS, other federal, state, and local governmental agencies, and industrial partners.
HHS PHEMCE IMPLEMENTATION PLAN:
HHS, through the Public Health Emergency Medical Countermeasures Enterprise, has developed both a Strategy and an Implementation Plan to efficiently integrate the requirements for, and the advanced development and acquisition of, medical countermeasures for CBRN threat agents. The first stage was the development of the HHS Public Health Emergency Medical Countermeasures Enterprise Strategy for Chemical Biological, Radiological and Nuclear Threats (HHS PHEMCE Strategy), which was published in the Federal Register on 20 March 2007 and is consistent with the principles expressed by the White House in Medical Countermeasures against Weapons of Mass Destruction.
The second stage was the development of the HHS PHEMCE Implementation Plan for CBRN Threats (HHS PHEMCE Implementation Plan). This is a prioritized plan with near-term (FY07-08), mid-term (FY09-13) and long-term (FY14-23) goals for research, development, and acquisition of medical countermeasures that is consistent with the guiding principles and priority setting criteria defined in the HHS PHEMCE Strategy. The HHS PHEMCE Implementation Plan, published in the Federal Register on 23 April 2007, is supported by a number of HHS funding streams, including NIH biodefense research and development, advanced development monies, Strategic National Stockpile resources and the Special Reserve Fund authorized under Project BioShield.
PROJECT BIOSHIELD:
The Project BioShield Act of 2004 (Project BioShield) was enacted to accelerate the acquisition and availability of safe and effective medical countermeasures to protect the United States from CBRN threats. Project BioShield created a $5.6 billion Special Reserve Fund for use over 10 years (FY 2004 - FY 2013) to acquire medical countermeasures for Strategic National Stockpile.
BARDA:
BARDA, in the Pandemic and All-Hazards Preparedness Act, gives HHS the authority to invest in medical countermeasure advanced development that will carry products across the so-called "Valley of Death" to meet medical countermeasure requirements, reduce risk to both medical countermeasure developers and the Government, and promote innovation.
ATTENDEES:
The workshop is an open meeting that seeks to bring together representatives from the pharmaceutical and biotechnology industries, professional societies, state and local public health organizations, the academic research and development community, public interest groups, stakeholder federal agencies, and Congress.
FOR MORE INFORMATION:
For more information, please see the OPHEMC website at http://www.hhs.gov/aspr/ophemc/index.html.
BARDA INDUSTRY DAY:
HHS is also hosting a BARDA Industry Day on August 3, 2007. This unique event will provide an opportunity for industry representatives and other interested parties to demonstrate the operation and effectiveness of relevant biodefense technologies in vaccines, diagnostics, and therapeutics. For more information on presenting at or attending the BARDA Industry Day, please visit http://www.hhs.gov/aspr/ophemc/barda/index.html
|
|
|
|
|
|
|
|
Site maintained by Professional and Scientific Associates, Inc. 2100 Reston Parkway, Ste. 300, Reston, VA 20191
|
|
|
|